Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Agios Pharmaceuticals
AGIO
Agios Pharmaceuticals
Mounting Pricing Pressures And Delays Will Depress Future Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
14 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$37.00
0.03% overvalued
intrinsic discount
16 Aug
US$37.01
Loading
1Y
-17.8%
7D
3.5%
Author's Valuation
US$37.0
0.03% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$37.0
0.03% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-389m
764m
2014
2017
2020
2023
2025
2026
2028
Revenue US$220.5m
Earnings US$35.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
54.55%
Biotech revenue growth rate
13.35%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$35.84m
Earnings '28
x
76.67x
PE Ratio '28
=
US$2.75b
Market Cap '28
US$2.75b
Market Cap '28
/
61.88m
No. shares '28
=
US$44.40
Share Price '28
US$44.40
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$36.47
Fair Value '25
